March 2014
Jan 2014
Aug 2013
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company's pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.
Address
Suite 200, 4505 Emperor Blvd
DURHAM, NC 27703
United States
DURHAM, NC 27703
United States
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -126.79% | -148.64% |
| Operating margin | -149.58% | -128.89% |
| EBITD margin | - | -119.81% |
| Return on average assets | -34.64% | -55.97% |
| Return on average equity | - | -544.61% |
| Employees | 40 |
No comments:
Post a Comment